- Approximately 5 million people globally have ulcerative colitis.
- Although there is currently no cure for ulcerative colitis, medications can help treat the condition’s symptoms.
- The FDA recently approved a new medication by Eli Lilly, mirikizumab, sold under the brand Omvoh, for treating moderately to severely active ulcerative colitis in adults.
About
There is currently no cure for ulcerative colitis. The symptoms of the condition are normally treated through medications and possible surgery, as well as
On October 26th, the Food and Drug Administration (FDA) approved a new medication for treating moderately to severely active ulcerative colitis in adults.
Called Omvoh™ (mirikizumab-mrkz), the drug made by Eli Lilly and Company is the first and only
Mirikizumab — which was recently approved under the brand name Omvoh — is an interleukin-23p19 antagonist. The first three doses of the drug are administered by intravenous infusion, followed by subcutaneous injections administered once every four weeks.
Over-activation of the
“Mirikizumab is the first antibody targeting p19/interleukin-23 to be approved for the treatment of ulcerative colitis,” said Dr. Bruce Sands, chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Mount Sinai Health System, and senior author of the clinical trial, and a paid consultant for Lilly USA, LLC. “Its performance in both induction and maintenance phases of the clinical trials is truly impressive.”
The FDA’s approval of Omvoh was based on results from two phase 3 clinical trials published in June 2023.
After 12 weeks of receiving Omvoh,…
Read the full article here